Skip to main content

The list price of KISQALI tablets is $6,064-$15,162 per month* based on the dose you're taking, but the amount you pay will depend on your insurance plan. The information below outlines what you may pay based on the type of insurance you have. Please speak with your insurance company or pharmacist to better understand your exact cost and the details of your plan.

Novartis Oncology is committed to making treatment with KISQALI as affordable as possible. You may qualify for financial assistance and other support based on your situation.

*Based on WAC Pricing as of January 2022.

71% of KISQALI prescriptions cost between $0-$10 per month with the remaining prescriptions having a median cost of $0

KISQALI prescriptions cost chart

Data source is IQVIA FIA claims data Dec 2020—Dec 2021.

75% of KISQALI prescriptions cost between $0-$10 per month with the remaining prescriptions having a median cost of $0

KISQALI prescriptions cost chart

Data source is IQVIA FIA claims data Dec 2020—Dec 2021.

100% of KISQALI prescriptions cost between $0-$10 per month

KISQALI prescriptions cost chart

Data source is IQVIA FIA claims data Dec 2020—Dec 2021.

We're committed to making treatment with KISQALI as affordable as possible. Read below to learn about ways you may be able to save on your KISQALI prescription.

1 FREE Treatment Cycle of KISQALI and/or FEMARA


Patients are eligible to receive a 1-treatment cycle supply of any one of the following at no cost.*

  • KISQALI® (ribociclib)

  • FEMARA® (letrozole)

  • letrozole

  • KISQALI + FEMARA

  • KISQALI + letrozole

  • KISQALI FEMARA Co-Pack

Call 1-800-282-7630 or visit www.FreeTreatmentVoucher.com to receive your free treatment voucher.  

*No purchase required of the KISQALI FEMARA Co-Pack, or KISQALI or FEMARA (including generic letrozole). This offer is available for patients with a valid prescription for the KISQALI FEMARA Co-Pack, or for KISQALI and/or FEMARA (including generic letrozole), including for patients who have not been prescribed KISQALI or another Novartis product. 

KISQALI 5-Treatment Cycle Access

Patients with commercial insurance who are still waiting for their coverage to take effect for the KISQALI FEMARA Co-Pack or KISQALI may be eligible for an additional supply of KISQALI that could continue for up to 5 treatment cycles.†


For more information, talk to your doctor or call 1-800-282-7630.


Limitations apply. Eligible patients must have commercial insurance, a completed Service Request Form, and be experiencing a delay in obtaining coverage for KISQALI. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, Tricare, or any other federal or state program. No purchase necessary. Participation is not a guarantee of insurance coverage. Once coverage is approved, patients will no longer be eligible. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

KISQALI and/or FEMARA $0 Co-Pay  
You may be eligible for immediate co-pay savings on your next prescription of KISQALI and/or FEMARA (including generic letrozole).

  • Eligible patients with private insurance may pay $0 per month

  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product

To find out if you are eligible for the Novartis Oncology Universal Co-Pay Program, 
call 1–877–577–7756 or visit www.CoPay.NovartisOncology.com.
  

Limitations apply. This offer is only available to patients with private insurance. The Program is NOT AVAILABLE for patients that are enrolled in Medicare, Medicaid, or any other federal or state health care program. Use of this offer for FEMARA (or generic letrozole) does not require a KISQALI prescription. Offer is NOT valid for purchases of FEMARA only by California or Massachusetts residents. Novartis reserves the right to rescind, revoke, or amend this Program without notice. For full terms and conditions, visit www.CoPay.NovartisOncology.com or 
call 1–877–577–7756.

Find KISQALI treatment information and patient support resources at KISQALI.com.

Our commitment to patients.

At Novartis Oncology, patients are our priority. That's why we go beyond the medicines we make to bring you the support and resources you need to help you during your journey. From financial assistance to online support, learn how we can make it as simple as possible for you to get connected to resources that can help.

Learn more

Contact Us:

Call 1-800-282-7630

Important Safety Information

What is the most important information I should know about KISQALI ?

KISQALI may cause serious side effects, including:

Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or...

Indications

KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with:

  • an aromatase inhibitor as the first endocrine-based therapy; or...
Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE